Patent EP-2644704-A1 (EP)
Inventor: LUEKING ANGELIKA
IPC: C12Q1/68
Filed: 2012-03-27
Abstract: Use of marker sequences for diagnosing rheumatoid arthritis, is new, where at least one marker sequence consists of part of sequences of SEQ ID NO: 1-78, complementary DNA (cDNA) of SEQ ID NO: 79-156, genomic sequences, which contain one of the sequences of 1-156 and/or a protein encoded by the sequence of 1-156 or a part of sequence or its fragment, and sequences are not defined and identified by a method including identifying a marker sequence candidate by differential screening with protein biochips from each of a cDNA expression library of a patient with and without arthritis. Use of marker sequences for the diagnosis of rheumatoid arthritis, is new, where at least one marker sequence consists of part of sequences of SEQ ID NO: 1-78, complementary DNA (cDNA) of SEQ ID NO: 79-156, genomic sequences, which contain one of the sequences of 1-156 and/or a protein encoded by the sequence of 1-156 or a part of sequence or its fragment, and the marker sequences are not defined and identified by a method comprising identifying a marker sequence candidate by differential screening with protein biochips from each of a cDNA expression library of a patient with rheumatoid arthritis and a subject without rheumatoid arthritis, expressing the marker sequence candidates to produce the encoded proteins and/or part of proteins (peptides), preparing Luminex (RTM: Analyzer) beads to which one or more proteins produced and/or part of proteins are coupled, where biomarkers for the rheumatoid arthritis such as of cinnamoyl CoA reductase (CCP) are optionally coupled to the Luminex (RTM: Analyzer) beads, and validating the marker sequence candidates using samples of patients with the rheumatoid arthritis and the subjects without rheumatoid arthritis, where the validation step is optionally performed in the presence of the known biomarkers for the rheumatoid arthritis. Independent claims are included for: (1) a method-I of diagnosing rheumatoid arthritis, comprising applying (a) the marker sequence consisting of part of sequences of SEQ ID NO: 1-78, cDNA of SEQ ID NO: 79-156, genomic sequences that comprise one of the sequences of 1-156 and/or a protein encoded by the sequence of 1-156 or a part of sequence or its fragments on a support, preferably bead, (b) contacting a patient with a body fluid or tissue extract, and (c) detecting an interaction of body fluid or tissue extract with the marker sequence; (2) a method-II of stratifying, preferably risk stratifying or therapy management of a patient with rheumatoid arthritis, comprising determining the marker sequence consisting of part of sequences of SEQ ID NO: 1-78, cDNA of SEQ ID NO: 79-156, genomic sequences that comprise one of the sequences of 1-156 and/or a protein encoded by the sequence of 1-156 or a part of sequence or its fragments to or from a patient to be examined; (3) assay, protein biochip comprising an arrangement including the marker sequence; (4) use of an assay for identifying and characterizing a substance for the rheumatoid arthritis comprising an agent for detecting a binding success, where the arrangement or assay is contacted with at least one substance to be examined, and is detected with the binding success; (5) a diagnostic tool for the diagnosis of rheumatoid arthritis comprising the marker sequence; and (6) a target for the treatment and therapy of rheumatoid arthritis comprising the part of sequences.